The Mater Private Hospital is a private hospital business. Its main hospital is located just to the east of the Mater Misericordiae University Hospital in Dublin, Ireland.

During the past decade, Mater Private Hospital conducted 16 clinical trials. In the 10-year time frame, 16 clinical trials started and 18 clinical trials were completed, i.e. on average, 112.5% percent of trials that started reached the finish line to date. In the past 5 years, 5 clinical trials started and 9 clinical trials were completed. i.e. 180% of trials that started reached the finish line.

Out of the total clinical trials conducted in "Mater Private Hospital" #1 sponsor was "Cancer Trials Ireland" with 7 trials, followed by "National Cancer Institute (NCI)" with 6 trials sponsored, "Pfizer" with 5 trials sponsored, "Hoffmann-La Roche" with 4 trials sponsored and "University of Sydney" with 4 trials sponsored. Other sponsors include 13 different institutions and companies that sponsored additional 22 trials in total.

In terms of collaborators to trials, out of the total clinical trials conducted in "Mater Private Hospital" #1 collaborator was "Australian and New Zealand Urogenital and Prostate Cancer Trials Group" with 3 trials as a collaborator, "Cancer Trials Ireland" with 3 trials as a collaborator, "European Organisation for Research and Treatment of Cancer - EORTC" with 3 trials as a collaborator, "Astellas Pharma Inc" with 2 trials as a collaborator and "Canadian Cancer Trials Group" with 2 trials as a collaborator. Other collaborators include 24 different institutions and companies that were collaborators in the rest 29 trials.

According to Clinical.Site data, the most researched conditions in "Mater Private Hospital" are "Breast Cancer" (6 trials), "Prostate Cancer" (4 trials), "Colorectal Cancer" (3 trials), "Coronary Artery Disease" (2 trials) and "Metastatic Prostate Cancer" (2 trials). Many other conditions were trialed in "Mater Private Hospital" in a lesser frequency.

Most popular intervention types in "Mater Private Hospital" are "Drug" (32 trials), "Other" (11 trials), "Biological" (7 trials), "Device" (6 trials) and "Radiation" (4 trials). Other intervention types were less common.

The name of intervention was led by "Laboratory Biomarker Analysis" (5 trials), "Docetaxel" (4 trials), "Enzalutamide" (4 trials), "Cyclophosphamide" (3 trials) and "Placebo" (3 trials). Other intervention names were less common.

The vast majority of trials in "Mater Private Hospital" are 19 trials for "All" genders, 15 trials for "Female" genders and 9 trials for "Male" genders.

Currently, there are NaN active trials in "Mater Private Hospital". undefined are not yet recruiting, 5 are recruiting, 15 are Active, not recruiting, and undefined are Enrolling by invitation. In total, there were 18 completed trials in Mater Private Hospital, undefined suspended trials, and 4 terminated clinical trials to date.

Out of the total trials that were conducted in Mater Private Hospital, 1 "Phase 1" clinical trials were conducted, 10 "Phase 2" clinical trials and 23 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 1 trials, and there were also 4 trials that are defined as “Not Applicable".